Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, executed a sale of 3,000 shares of the company’s common stock on March 16, 2026. The shares changed hands at $144.23 apiece, producing a total transaction value of $432,689. At the time of the sale, Gilead shares were trading near $144.40, reflecting a 29% increase over the prior six months and a 34% gain over the trailing year.
After completing the sale, Dickinson retains direct ownership of 179,191 Gilead shares. The disposition was carried out pursuant to a Rule 10b5-1 trading plan that Dickinson adopted on August 29, 2024.
Separately, analysis from InvestingPro included with market commentary indicates that Gilead appears undervalued at current prices and that the company holds a "GREAT" financial health score. The analysis also notes that Gilead has increased its dividend for 11 consecutive years and references a Pro Research Report covering Gilead and other U.S. equities for subscribers seeking deeper company-level detail.
Several corporate and clinical developments have converged with the insider transaction. Gilead recently presented positive Phase 3 data for an investigational HIV regimen combining bictegravir and lenacapavir, demonstrating that the two-drug combination was non-inferior to existing multi-tablet regimens in maintaining virologic suppression. In M&A activity, Gilead announced an agreement to acquire Aclx for $7.8 billion, a purchase price that reflects a 68% premium over the 30-day average trading price for Aclx.
Market analysts have responded to Gilead’s recent news flow with mostly favorable assessments. UBS has reiterated a Buy rating on Gilead and maintained a $175 price target. Cantor Fitzgerald kept an Overweight rating and raised its sales forecast for Yeztugo to $1.1 billion for 2026, above consensus estimates. Bank of America Securities reiterated a Buy rating as well, citing strong early prescription data for Yeztugo that include a 90% U.S. insurance coverage rate and weekly prescription volumes that showed approximately 5% week-over-week growth.
The report also referenced activity at Amgen in the broader sector: Jefferies initiated coverage of Amgen with a Hold rating, pointing to pipeline risks and a $9.9 billion loss of exclusivity gap. Jefferies characterized Amgen’s shares as fairly valued at current levels while noting potential for growth in its base business.
Taken together, the insider sale by Gilead’s CFO occurs amid positive clinical validation for an investigational HIV combination, a large-scale acquisition priced at a significant premium, and sustained analyst support for Gilead’s commercial prospects. The transaction details - the number of shares, the per-share price, the total value, the remaining direct ownership, and the Rule 10b5-1 plan adoption date - are recorded as reported.
Summary
Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares on March 16, 2026, at $144.23 per share, totaling $432,689. The sale was executed under a Rule 10b5-1 plan adopted on August 29, 2024. The company is in the spotlight for positive Phase 3 HIV data, a $7.8 billion acquisition of Aclx at a 68% premium, and favorable analyst commentary tying to Yeztugo uptake.